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Abstract
Background: Pulmonary complications are common in primary immunodeficiency diseases (PID) and contribute to
morbidity and mortality in these patients. However, their varied presentation and a general lack of awareness of PID
in this setting make early diagnosis and treatment difficult. The aim of this study was to define the warning signs of
PID in patients with respiratory manifestations, the necessary diagnostic tests, and the therapeutic management of
both children and adults.
Methods: A review of the literature was performed, and 43 PID interdisciplinary specialists were consulted.
Results: This document identifies the pulmonary and extrapulmonary manifestations that should prompt a suspicion
of PID, the immunological and respiratory tests that should be included in the diagnostic process according to the
level of care, recommendations regarding the use of immunoglobulin replacement therapy according to the specific
immunodeficiency, and the minimum recommended immunological and pulmonary monitoring in these patients.
Conclusions: This document is the first to combine scientific evidence with the opinion of a broad panel of experts
specializing in the treatment of patients with immunodeficiencies. It aims to provide a useful tool for all practitioners
who are regularly involved in the management of these patients.
Keywords: “Immunoglobulins/deficiency”[mesh], “Antibodies/deficiency”[mesh], “Immunoglobulins/administration and
dosage”[mesh], “Respiratory Tract Infections”[mesh], “Immunologic Deficiency Syndromes”[mesh]
Background
Immunodeficiency diseases (ID) are disorders involving
a quantitative and/or functional disorder in the immune
response [1] that may lead to a greater risk of infections,
immune dysregulation, autoimmune phenomena, in-
flammation, and cancer. These IDs are classified as pri-
mary immunodeficiency diseases (PIDs) if their origin is
genetic, and secondary (SID) if acquired.
PIDs comprise a heterogeneous group of more than 300
diseases. The Primary Immunodeficiencies Classification
Committee of the International Union of Immunological
Societies (IUIS) divides PIDs into 8 groups (9, if we in-
clude PID phenocopies), depending on their clinical and
immunological phenotype [2]. The various congenital or
acquired defects can affect both the innate and the
acquired immune system [3]. The most common PIDs are
predominantly antibody disorders (56.66%), other well
defined PIDs (13.91%), phagocytic disorders (8.73%), pre-
dominantly T cell deficiencies (7.47%), and complement
deficiencies (4.89%) [4].
The prevalence of PID in Europe and the United
States ranges from 41 to 83 per 100,000 inhabitants, de-
pending on the study [5, 6]. The diagnosis of PID often
emerges from a picture of recurrent or unusual infec-
tions, autoimmune diseases, inflammatory processes or
cancers. A careful approach must be taken in the early
detection of these signs, in order to avoid unnecessary
testing, but without delaying diagnosis. However, since
their clinical presentation varies widely and understand-
ing of this area is often limited, underdiagnosis and
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delayed diagnosis are common, generating significant
morbidity and mortality [7] and a major social and eco-
nomic impact [8]. Generally, the early clinical manifesta-
tions of PID occur during childhood, but they also are
frequently encountered in the second or third decade of
life, or even in older patients [9]. Moreover, there are
different clinical presentations across various age cat-
egories and these presentations in children could widely
differ from adult patients with PID [10].
New warning signs alerting to a suspicion of PID are
being increasingly described, based on clinical presenta-
tions - mainly infectious diseases - and, in some cases,
family history. Fifteen years ago, the Jeffrey Modell
Foundation (JMF) defined the warning signs of sus-
pected PID in children and adults [8, 11]. This docu-
ment is a useful basis, but one that needs to be updated,
as it does not refer to the autoimmune, inflammatory or
malignant manifestations of PIDs, which can be the
main clinical presentation in some of these diseases [12].
In addition, a follow-up study by Subbarayan et at
highlighted the low sensitivity and specificity of these
warning signs, recommending that PID awareness initia-
tives should be mainly targeted at hospital pediatricians
and families with a history of PID although these initia-
tives should also include the general public [13].
Pulmonary complications in PID are common and sig-
nificantly contribute to the morbidity and mortality of
patients. Recurrent respiratory tract infections often
constitute the first warning sign in some PIDs and are
often the main cause of death in adults with PID [14,
15].
The aim of this study was to define which warning
signs should alert to the suspicion of PID in patients
with respiratory manifestations, and to develop pro-
posals for intervention in these cases. This document is
aimed at primary care (PC) professionals and specialists
who see both adult and pediatric patients with respira-
tory diseases. This study is part of the ID-Signal Project,
which aims to generate a series of documents based on
the clinical manifestations of IDs dedicated to
non-immunologists who may take care of patients with
PID or SID in their clinical practice.
Methods
Initially, an interdisciplinary expert group formed of 2
pulmonologists, 2 immunologists and 2 pediatricians
specializing in immunodeficiencies identified items to be
addressed in the areas of clinical and laboratory testing,
diagnostic imaging, functional tests, and therapeutic
approach, and prepared a series of recommendations. A
review of the literature was then performed, which acted
as a basis for a discussion of the contents of the docu-
ment in an in-person meeting. The main conclusions
and recommendations were forwarded to an external
panel of experts for their individual evaluation, depend-
ing on their specialty. Although we could have done a
Delphi process involving at least two rounds, we pre-
ferred a single consultation to have a general view of the
opinion of a larger group of experts and to make the
process easier. The external panel consisted of 43
experts from all over Spain, with experience in the diag-
nosis and treatment of PID, working in Spanish National
Health System centers. In total, 19 immunologists spe-
cializing in adults (adult immunologists, AI), 15 pediatric
specialists in immunodeficiencies (pediatric immunolo-
gists, PI), 5 pulmonologists taking care of adults (adult
pulmonologists, AP), and 4 pediatric specialists in pul-
monology (pediatric pulmonologists, PP) participated.
This panel indicated their level of agreement on a scale
of 1 to 4, with 1 reflecting “strongly disagree” and 4
“strongly agree”, and they could also add comments when
necessary. The results were pooled and the percentages of
votes in the categories 1 and 2 (disagree) and in the cat-
egories 3 and 4 (agreement) were calculated. Unanimity
was determined when 100% of the experts agreed with
recommendation/conclusion; consensus, when at least
80% of the experts agreed without unanimity; majority,
when more than 65% and less than 80% of the experts
agreed with the recommendation/conclusion; and dis-
agreement, when the percentage of agreement was 65% or
less.
Results and discussion
Lung diseases that should prompt a suspicion of PID
In general, lung complications caused by PID include re-
spiratory tract infections, interstitial lung disease (ILD),
and cancers [14]. Recurrent lung infections are often the
first warning sign in both adult and pediatric PID pa-
tients. These recurrent infections often cause permanent
lung damage if appropriate treatment is not promptly
initiated. Usually, there are also frequent upper respira-
tory infections previous to the lower ones, so an optimal
pulmonary management should encompass the upper
airway [16]. Airway damage can manifest as air trapping,
thickening of the bronchial walls, atelectasis and/or
bronchiectasis [14, 17]. The pathogens most commonly
associated with pneumonia in patients with ID will de-
pend on the type of immunodeficiency presented by the
patient but generally include Streptococcus pneumoniae
and Haemophilus influenzae, followed by Mycoplasma
spp., Staphylococcus spp., Moraxella spp., Pseudomonas
aeruginosa, and other viral pathogens, and more rarely
Pneumocystis jirovecii and various fungi [18].
However, since mortality due to infectious complica-
tions has declined, non-infectious complications have
begun to account for a large number of the poor clinical
outcomes observed in some of these patients [19]. Thus,
several histological patterns of ILD have been identified
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in patients with PID, especially in those with a diagnosis
of common variable immunodeficiency disease (CVID),
including granulomatous lung disease, lymphoid intersti-
tial pneumonia (LIP), non-specific interstitial pneumonia
(NSIP), and organizing pneumonia, and more than one
may co-exist in the same patient [14].
The patient profile (adult or pediatric) and pulmon-
ary manifestations (infectious or non-infectious) that
lead to a consultation in PC or with a respiratory
medicine specialist may be different. Manifestations
that should prompt a suspicion of PID are included
in Table 1. A respiratory medicine specialist must
ensure that pneumonia is confirmed on radiology: this
will be suggestive of PID, particularly if disease
appears in different sites. Cases of slow-progressing
disease must be investigated, and pneumonias that do
not resolve with multiple course of antibiotics and
require hospital admission, intravenous antibiotics or
intensive care assistance, should be noted, along with
a high frequency of pneumonias across time (one
pneumonia per year for more than one year).
Slow-progressing pneumonitis or bronchitis in an in-
fant that requires admission, particularly in the inten-
sive care unit, should be considered as potential
Table 1 Respiratory manifestations indicating a suspicion of PID in primary care and pulmonology clinics





Recurrent bronchial infections (≥ 2/year), with cough and purulent
expectoration
23* (AI, AP) 87.0 Consensus
Idiopathic bronchiectasis 23* (AI, AP) 100.0 Unanimity
Recurrent pneumonias** 23* (AI, AP) 100.0 Unanimity
Chronic bronchial infection 23* (AI, AP) 91.3 Consensus
Need for prolonged antibiotic treatment for respiratory infections 23* (AI, AP) 95.7 Consensus
Pediatric patient
Recurrent pneumonias** 19 (PI, PP) 100.0 Unanimity
Idiopathic bronchiectasis 19 (PI, PP) 100.0 Unanimity





Adult and pediatric patients
Recurrent bronchial infections (≥ 2/year), with cough and purulent
expectoration
43 (AI, AP, PI, PP) 86.0 Consensus
Idiopathic bronchiectasis 43 (AI, AP, PI, PP) 100.0 Unanimity
Recurrent pneumonias** 43 (AI, AP, PI, PP) 97.7 Consensus
Chronic bronchial infection 43 (AI, AP, PI, PP) 90.7 Consensus
Need for prolonged antibiotic treatment for respiratory infections 43 (AI, AP, PI, PP) 93.0 Consensus
Pulmonary abscess and pneumatocele 43 (AI, AP, PI, PP) 90.7 Consensus
Infections caused by rare or opportunistic microorganisms 43 (AI, AP, PI, PP) 100.0 Unanimity
Infants
Severe infantile bronchiolitis or pneumonia 43 (AI, AP, PI, PP) 93.0 Consensus
NON-INFECTIOUS
Adult and pediatric patients
Granulomatous-lymphocytic interstitial lung disease 43 (AI, AP, PI, PP) 100.0 Unanimity
Bronchiolitis obliterans 43 (AI, AP, PI, PP) 72.1 Majority
Lymphoproliferative syndrome 43 (AI, AP, PI, PP) 90.7 Consensus
Alveolar proteinosis 43 (AI, AP, PI, PP) 86.0 Consensus
Recurrent serositis 43 (AI, AP, PI, PP) 76.7 Majority
Thymic disorders: thymoma (adult), thymic aplasia (infant) 43 (AI, AP, PI, PP) 100.0 Unanimity
AI: adult immunologists; AP: adult pulmonologists; PC: primary care; PI: pediatric immunologists; PID: primary immunodeficiency disease; PP:
pediatric pulmonologists
*One value is missing. ** One pneumonia per year for more than one year
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manifestations of PID, although severe bronchiolitis
may be relatively common in healthy infants.
Classification of respiratory diseases by PID type
PIDs have been divided into several categories, accord-
ing to their clinical characteristics and immune system
involvement. In any case, we must remember that inclu-
sion in one category or another involves an important
academic component, and in routine practice, the clin-
ical context of the patient will help guide their classifica-
tion. There are some lung manifestations that should
lead to the suspicion of a specific PID. This is the case
of pneumatocele and AD-hyperIgE syndrome, bronchi-
ectasis and antibody deficiencies, severe bronchiolitis
and severe combined immunodeficiencies or pulmonary
fungal infections and phagocyte disorders, among others.
However, most lung diseases can occur in a wide range
of PID, in which a wide but phased diagnostic protocol
is recommended.
Table 2 identifies the respiratory pathogens that are
most commonly associated with each type of PID; several
manifestations only achieved a majority agreement but
not consensus, possibly due to the limited experience
available in certain types of manifestations. Discrepancies
were found for other manifestations (“abscess and pneu-
matocele” and “bronchiolitis obliterans”, with agreements
of 55.8 and 60.5%, respectively).
Table 2.
EXTRAPULMONARY manifestations that should suggest
PID
It is very important that the specialist who evaluates a pa-
tient with suspected PID due to lung problems also takes
in account the presence of extrapulmonary manifestations
that might support the clinical suspicion of PID, since one
of the main characteristics of PID is its ability to affect
multiple organs or systems simultaneously or sequentially.
PID may present with skin [20–22], gastrointestinal [23],
or autoimmune [24–26] manifestations, among others.
Table 3 (adapted from JC Aldave [27]) lists the main extra-
pulmonary clinical manifestations, with their degrees of
agreement. Two common extrapulmonary manifestations
did not reach consensus.
On the other hand, there are some histopatological
findings which would prompt the clinician to consider a
diagnosis of PID before having the suspicious of it. This
is the case of granulomas or the absence of plasma cells
in a gastrointestinal biopsy.
Diagnostic tests to be performed in patients with
suspected PID
A large number of PIDs can be diagnosed from a de-
tailed clinical history that includes a family history of
PID, consanguinity, or family members who died at a
young age, a comprehensive physical examination, blood
tests, and a determination of serum immunoglobulin
(Ig) levels. These tests are available in the vast majority
of laboratories, even in PC. The physical examination
should be detailed and ordered by body system, and it is
important to assess the patient’s nutritional status, with
particular attention to height and weight and sequelae
from previous infections. The presence of lymphadenop-
athies or the absence of nodal chains, tonsils, hepatos-
plenomegaly, etc. must be determined, since in some
cases these parameters may orient the professional to-
wards a specific PID. A complete blood count (CBC)
with a differential count provides important information
on suspected cytopenias (neutropenia, monocytopenia,
lymphopenia, or thrombocytopenia) and qualitative cel-
lular changes [9]. The determination of serum Igs (IgG,
IgM, IgA, and IgE) is the first step in the evaluation of
humoral immunity, and will help diagnose or at least
point to a suspicion of quantitative Ig deficiencies, such
as congenital agammaglobulinemia, CVID, or selective
IgA deficiency, and humoral changes associated with
other defects, such as hyper-IgE or hyper-IgM syndrome
[9]. On the other side, quantification of calculated globu-
lin (CG, total protein minus albumin [28]), T-cell recom-
bination excision circles (TREC) and kappa-deleting
element recombination circles (KREC) may help identify
PIDs early in PC. Recently, a study by Pecoraro et al
showed that a screening calculated globulin test could
be used as a tool to reduce diagnostic delays, improve
long-term prognosis and reduce the healthcare costs of
antibody deficiency [29].
There are obvious differences between diagnosis in chil-
dren and adults since, usually, most severe PID are diag-
nosed in childhood while recurrent respiratory infections,
which can be caused by many other non-immunological
entities and are the clue for the diagnosis during adult-
hood. Adolescents are a special population with mixed
manifestations. Therefore, first line diagnostic tests in
adults are almost specifically based on ruling primary anti-
body deficiency out (immunoglobulin levels and antibody
production assessment), while clinical manifestations will
orient the initial tests in childhood (e.g. burst oxidation
tests in invasive fungal infections, complement pathway
assessment if recurrent bacteremia...).
It is important to assess the results according to the
reference values for each age, since there are significant
differences which, if not taken into account, can cause
PID to be overlooked [30]. In addition, it is always im-
portant that the suspected diagnosis is oriented to avoid-
ing unnecessary studies that result in a waste of time
and resources. However, when the diagnosis is uncertain
and suspicion is high, additional tests, such as functional
or molecular studies, are needed, and these must be
conducted in reference centers. In fact, some of the
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Table 2 Common respiratory manifestations by PID type
Common respiratory manifestations by PID type N (Composition of panel) Votes in agreement (%) Degree of agreement
Predominantly T cell deficiency (combined and PID-related syndromes)
Recurrent bronchitis 43 (AI, AP, PI, PP) 72.1 Majority
Idiopathic bronchiectasis 43 (AI, AP, PI, PP) 76.7 Majority
Recurrent pneumonias* 43 (AI, AP, PI, PP) 88.4 Consensus
Repeated pneumonia in child 43 (AI, AP, PI, PP) 88.4 Consensus
Chronic bronchial infection 43 (AI, AP, PI, PP) 79.1 Majority
Prolonged antibiotic treatment with poor response 43 (AI, AP, PI, PP) 86.0 Consensus
Abscess and pneumatocele 43 (AI, AP, PI, PP) 55.8 Discrepancy
Infections caused by rare microorganisms 43 (AI, AP, PI, PP) 100.0 Unanimity
Pneumonitis or bronchitis with hospitalization in infants 43 (AI, AP, PI, PP) 86.0 Consensus
Interstitial lung disease 43 (AI, AP, PI, PP) 93.0 Consensus
Bronchiolitis obliterans 43 (AI, AP, PI, PP) 67.4 Majority
Alveolar proteinosis 43 (AI, AP, PI, PP) 76.7 Majority
Absent thymus or aplasia 43 (AI, AP, PI, PP) 95.3 Consensus
Antibody deficiencies
Recurrent bronchitis 43 (AI, AP, PI, PP) 90.7 Consensus
Idiopathic bronchiectasis 43 (AI, AP, PI, PP) 97.7 Consensus
Recurrent pneumonias* 43 (AI, AP, PI, PP) 97.7 Consensus
Repeated pneumonia in child 43 (AI, AP, PI, PP) 97.7 Consensus
Chronic bronchial infection 43 (AI, AP, PI, PP) 90.7 Consensus
Prolonged antibiotic treatment with poor response 43 (AI, AP, PI, PP) 97.7 Consensus
Pneumonia due to encapsulated bacteria 43 (AI, AP, PI, PP) 97.7 Consensus
Interstitial lung disease 43 (AI, AP, PI, PP) 79.1 Majority
Bronchiolitis obliterans 43 (AI, AP, PI, PP) 60.5 Discrepancy
Pulmonary lymphoma 43 (AI, AP, PI, PP) 69.8 Majority
Thymoma 43 (AI, AP, PI, PP) 88.4 Consensus
Immune deregulation
Recurrent bronchitis 43 (AI, AP, PI, PP) 69.8 Majority
Idiopathic bronchiectasis 43 (AI, AP, PI, PP) 74.4 Majority
Chronic bronchial infection 43 (AI, AP, PI, PP) 65.1 Majority
Pneumonia due to encapsulated bacteria 43 (AI, AP, PI, PP) 67.4 Majority
Interstitial lung disease 43 (AI, AP, PI, PP) 81.4 Consensus
Phagocyte disorders
Recurrent pneumonias* 43 (AI, AP, PI, PP) 90.7 Consensus
Prolonged antibiotic treatment with poor response 43 (AI, AP, PI, PP) 88.4 Consensus
Abscess and pneumatocele 43 (AI, AP, PI, PP) 97.7 Consensus
Infections caused by rare microorganisms 43 (AI, AP, PI, PP) 97.7 Consensus
Alveolar proteinosis 43 (AI, AP, PI, PP) 69.8 Majority
Innate immunity disorder
Recurrent pneumonias* 43 (AI, AP, PI, PP) 97.7 Consensus
Pneumonia due to encapsulated bacteria 43 (AI, AP, PI, PP) 95.3 Consensus
Abscess and pneumatocele 43 (AI, AP, PI, PP) 83.7 Consensus
Infections caused by rare microorganisms 43 (AI, AP, PI, PP) 90.7 Consensus
Complement deficiency
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warning signs alone (signature signs) as opportunistic in-
fections, or high burden of infection should lead to the
referral of the patient to a higher level of care, so that
the appropriate tests could be performed.
With regard to tests that are specifically “pulmonary” in a
patient with suspected PID, tests adapted to the disease and
based on the clinical history are recommended: this is the
case for lung function tests and high-resolution computed
tomography (HRCT) to evaluate the lung structure, sputum
cultures to detect respiratory infections, and sputum cell
counts (neutrophils and eosinophils), among others [31].
Chest X-rays may be valuable in acute processes but they
are of little use for demonstrating the presence of bronchi-
ectasis or non-infectious pulmonary complications [32, 33].
The sensitivity of lung function tests for the early detection
of complications, such as bronchiectasis, is low, and they
should always include, if possible, the evaluation of diffusing
capacity of the lung for carbon monoxide (DLCO). HRCT,
on the other hand, is highly sensitive and specific, and has
an important role in the multidisciplinary approach to these
conditions, and in the detection, characterization, and
quantification of the degree of lung damage, the treatment
plan, and follow-up of patients. It is currently the gold
standard for the detection and characterization of bronchi-
ectasis [14, 16].
Tables 4 and 5 include immunological and pulmon-
ary tests, respectively, that must be performed when
PID is suspected, divided into levels of care. Even
though, in the last years the use of next-generation
sequencing has become an essential route for diag-
nosing PID and it is usually performed earlier in the
diagnostic algorithm of a patient with suspected PID.
Meanwhile, protein and functional testing remain to
be tested in reference centers if available. Although
all the immunological tests (Table 4) reached consen-
sus, some interesting proposals that the authors
agreed to include outside of the table are provided.
These include protein expression and genetic studies
in the third level for phagocyte deficiencies; determin-
ation of IgD levels, C-reactive protein (CRP), erythro-
cyte sedimentation rate (ESR) in the baseline level for
autoinflammatory diseases; serial determination of
mevalonate in urine during the acute episode in the
second level for autoinflammatory diseases; and re-
placement of tetanus serologies with tetanus/diph-
theria. Pulmonary tests (Table 5) were divided into
Table 2 Common respiratory manifestations by PID type (Continued)
Common respiratory manifestations by PID type N (Composition of panel) Votes in agreement (%) Degree of agreement
Recurrent bronchitis 43 (AI, AP, PI, PP) 65.1 Majority
Idiopathic bronchiectasis 43 (AI, AP, PI, PP) 72.1 Majority
Recurrent pneumonias* 43 (AI, AP, PI, PP) 83.7 Consensus
Repeated pneumonia in child 43 (AI, AP, PI, PP) 83.7 Consensus
Chronic bronchial infection 43 (AI, AP, PI, PP) 67.4 Majority
Autoinflammatory disease
Recurrent serositis 43 (AI, AP, PI, PP) 100.0 Unanimity
AI: adult immunologists; AP: adult pulmonologists; PI: pediatric immunologists; PID: primary immunodeficiency disease; PP: pediatric pulmonologists
* One pneumonia per year for more than one year
Table 3 Most common extrapulmonary manifestations of PID (adapted from JC Aldave, JFM) [27]
MOST COMMON EXTRAPULMONARY MANIFESTATIONS OF PID N (Composition of panel) Votes in agreement (%) Degree of agreement
Recurrent or complicated sinusitis 43 (AI, AP, PI, PP) 100.0 Unanimity
Recurrent or complicated otitis 43 (AI, AP, PI, PP) 93.0 Consensus
Other extrapulmonary infections requiring admission 43 (AI, AP, PI, PP) 88.4 Consensus
Ectodermal dysplasia 43 (AI, AP, PI, PP) 72.1 Majority
Chronic diarrhea or malabsorption 43 (AI, AP, PI, PP) 93.0 Consensus
Difficult-to-treat giardiasis 43 (AI, AP, PI, PP) 93.0 Consensus
Autoimmune cytopenias or other autoimmunity 43 (AI, AP, PI, PP) 93.0 Consensus
Lymphadenopathies and hepatosplenomegaly 43 (AI, AP, PI, PP) 97.7 Consensus
Related cancers, especially associated with viruses 43 (AI, AP, PI, PP) 83.7 Consensus
Family history of ID or consistent manifestations 43 (AI, AP, PI, PP) 88.4 Consensus
Post-vaccinal infections 43 (AI, AP, PI, PP) 79.1 Majority
AI: adult immunologists; AP: adult pulmonologists; ID: immunodeficiency; PI: pediatric immunologists; PID: primary immunodeficiency disease; PP:
pediatric pulmonologists
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adults and children. Discrepancies emerged regarding
the use of these tests in children, so they could not
be validated.
Immunoglobulin replacement therapy in PID
Immunoglobulin replacement therapy (IGRT) is essential
in patients with PIDs that directly affect B cell function
and antibody production, primarily in severe cases, but
also in patients in whom involvement is not obvious from
routine testing [34]. IGRT has brought about a significant
change in the prognosis of patients with PID. The mortal-
ity of CVID has fallen from 29% in 1971 (before the intro-
duction of intravenous Ig) to 19.6% in 2012 [35]. In
pulmonary complications of PID, IGRT has halved the
number of bacterial pneumonias [36]; however, this treat-
ment does not appear to improve other recurrent respira-
tory infections [36].
There are currently 6 PID phenotypes for which IGRT
is indicated or may be indicated [37]: agammaglobulin-
emia due to the absence of B cells; hypogammaglobuli-
nemia with impaired specific antibody production;
selective antibody deficiencies (IGRT use must be indi-
vidually evaluated); hypogammaglobulinemia with
normal-quality antibody response; isolated deficiency of
an IgG subclass with recurrent infections; and recurrent
infections due to an unknown immune mechanism.
Since IGRT was introduced in the 1980s, the adminis-
tered dose of Ig has been gradually increased to achieve
higher IgG plasma concentrations [38]. For example, in
the case of patients with CVID, IgG plasma concentra-
tions to prevent bacterial infections may range between
5 and 17 g/L, although trough concentrations of IgG of
around 8–10 g/L are often recommended. These levels
can be achieved with a dose range of 0.2–1.2 g/kg/
month. Doses must be individualized, and higher doses
are required in patients with bronchiectasis and those
with certain phenotypes [38].
IGRT can be administered by 2 routes: subcutaneous
(SCIG) and intravenous (IVIG); the muscular route has
fallen into disuse. There is also a facilitated SCIG which
improves its bioavailability and allows infusions every 3–
4 weeks [39]. Adequate doses administered by both
routes provide physiological IgG concentrations [40, 41],
although the kinetics are different: intravenous adminis-
tration produces a rapid increase in IgG plasma concen-
trations, while subcutaneous administration produces
more gradual increases in plasma levels [41, 42] and
more stable serum concentrations [40, 43]. SCIG can be
particularly beneficial in patients with low IgG concen-
trations despite intravenous treatment, since higher
mean serum values can be achieved with lower doses of
immunoglobulin [44–46]. Both routes of administration
have shown equivalence in terms of efficacy and safety
[37, 45, 47], although the incidence of serious systemic
adverse effects is higher with IVIG and more mild local
effects are observed with SCIG [42, 45, 48].
Different factors must be considered when selecting
the route of administration, as not all patients benefit
equally from both [49]. Firstly, SCIG is associated with a
better quality of life for both patients and their care-
givers [46, 50, 51]. A review of 25 studies showed im-
proved health-related quality of life in patients who
switched IVIG administration in the hospital for
home-administered SCIG [45]. This same review also
concluded that SCIG therapy was more cost-effective,
mainly due to the reduction in days missed from school
or work [45]. The subcutaneous route is also more ap-
propriate for patients with difficulties for venous access,
and does not appear to adversely affect renal function
[37, 41]. However, the patient must be trained, and the
Table 6 Minimum tests to be performed during monitoring of the patient with PID and respiratory symptoms




Patient visit every 6–12 months. 34 (AI, AP) 91.2 Consensus
Immunological studies (complete blood count, biochemistry with LDH and Igs)
every 6–12 months.
34 (AI, AP) 91.2 Consensus
In the event of RT with gammaglobulins, IgG trough values must be measured more
frequently, at least during dose adjustment.
34 (AI, AP) 100.0 Unanimity
Respiratory tests:
• Annual lung function tests are recommended every year.
• Spirometry must be performed every 4–6 months in the absence of lung disease.
• The sputum culture must be performed at each visit if patient is expectorating and
in case of any exacerbation.
9 (AP, PP) 100.0 Unanimity
Lung CT every 2–3 years if the patient has pulmonary involvement and every 5 years
otherwise. Radiation must be minimized in case of radiosensitive ID.
9 (AP, PP) 100.0 Unanimity
Extrapulmonary tests should be performed according to the patient’s symptoms or
manifestations.
43 (AI, PI, AP, PP) 97.7 Consensus
AI: adult immunologists; AP: adult pulmonologists; ID: immunodeficiency; Ig: immunoglobulins; LDH: lactate dehydrogenase; PI: pediatric immunologists; PID:
primary immunodeficiency disease; PP: pediatric pulmonologists; RT: replacement therapy
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equipment and infrastructure required for correct ad-
ministration may not be easily achieved for all patients.
Finally, patient preferences are fundamental when deci-
sions are being made. Multidisciplinary long-term moni-
toring programs must be implemented that are flexible
regarding the alternate use of both routes, depending on
the life circumstances of each patient [52, 53]. Despite
all, the decision of which route and location of therapy
is best may change with age and personal circumstances
and requires ongoing re-evaluation; however patients
who are stable and managing well with a specific route
should not be swapped onto different products for
non-clinical reasons.
Monitoring PID patients with pulmonary involvement
Survival and quality of life of patients with certain PIDs
has improved significantly in recent years, particularly as
a result of better diagnosis and treatment of infections
and other comorbidities, the development of highly po-
tent antimicrobial agents, and the development of spe-
cific therapeutic alternatives, such as IgG and others
[54]. However, we must not allow the reduction in the
number of infections and hospitalizations to generate a
lower perception of severity that might lead to a relax-
ation in the regular clinical monitoring of the disease
[9].
The decision on the frequency of evaluations of PID
patients depends on several factors, including the type of
PID, clinical conditions, and age. There is currently no
internationally agreed consensus on the follow-up of pa-
tients with PID and lung involvement, but it has been
suggested that patients should be evaluated at least once
every 6–12 months with a full clinical history and phys-
ical examination [9]. Whenever possible, this evaluation
should be performed by an expert in PID [55].
The literature reviewed proposes that the follow-up of
patients with pulmonary complications should include
serial lung function tests and imaging studies, along with
regular sputum cultures [9, 56]. Chest X-ray will only be
indicated if acute pulmonary involvement is suspected.
It is recommended that HRCTs are performed every 3–
5 years in patients under treatment, depending on their
clinical stability [57].
Table 6 sets out the recommendations on the mini-
mum tests to be performed during the clinical monitor-
ing of the PID patient with pulmonary symptoms.
Conclusions
This study is the first to focus on PID from a pulmonary
point of view, addressing the diagnosis, treatment and
follow-up of both adult and pediatric patients, while
simultaneously including the opinion and clinical experi-
ence of more than 40 experts from different fields and
specialties who regularly treat these deficiencies. This
document is intended to be a useful tool for both pri-
mary care professionals and specialists who are treating
patients with lung disease, helping them to identify the
warning signs of PID in order to make an early diagnosis
or else to refer the patient to a specialized unit, thus
avoiding unnecessary complications. Other approaches
that may help an early identification of PIDs should
include education and awareness for specialists. Finally,
future possible shortcomings of the study will involve
other medical specialties and other clinical manifesta-
tions of IDs.
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